We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Mid-Gestation Preeclampsia Screening Test Successfully Validated

By LabMedica International staff writers
Posted on 18 Jul 2012
Print article
A mid-gestation preeclampsia-screening test correctly identifies 80% of women at risk for the development of preterm preeclampsia.

Pronota’s (Ghent, Belgium) assay, which tests for five protein biomarkers such that in conjunction with blood pressure measurement offers an improvement to existing tests. Proteomics platforms of Pronota were used to identify, verify, and validate a panel of novel blood biomarkers, which are predictive of preeclampsia at the mid-gestation time point. An unbiased large-scale proteomics biomarker-discovery experiment was followed by verification of the results in 300 women who either subsequently developed preeclampsia or did not.

The predictive merit of the biomarker panel was subsequently confirmed in another study of 300 women from a different population. In this validation study, the screening test identified 80% of the women who developed preeclampsia that resulted in birth of a premature baby (preterm preeclampsia). Pronota achieved these results through a longstanding scientific collaboration with Prof. Baker from the University of Alberta (Edmonton, AB, Canada), Prof. North from King’s College, London (United Kingdom), and Dr. Myers from Manchester Maternal & Fetal Health Research Center (United Kingdom).

The cohort used for the study was compiled by the the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium who collected blood samples and gathered medical and lifestyle information from 5,600 women in six centers across Australia, New Zealand, the UK, and the Republic of Ireland over eight years. This controlled prospective study using high quality plasma samples and clinical data allowed for the rigorous and stepwise validation of Pronota’s test.

Dr. Jenny Myers, clinical senior lecturer, Manchester Maternal & Fetal Health Research Centre (United Kingdom) will present a discussion of the Pronota-SCOPE study at the International Society for the Study of Hypertension in Pregnancy meeting in Geneva (Switzerland) in July 2012.

Related Links:
Pronota
University of Alberta
King’s College, London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.